

APPENDIX

Ipsen EPE disclosure of transfers of value, in accordance with article 66, paragraph 7 of L. 4316/2014 and with SFEE's and EFPIA's disclosure code.

In accordance with article 66, paragraph 7 (a) and (b) of L. 4316/2014 any pharmaceutical company should disclose nominally any value granted/paid to Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs). In addition, EFPIA's (European Federation of Pharmaceutical Industries and Associations) and SFEE's (Hellenic Association of Pharmaceutical Companies) disclosure codes require by their members to disclose their transfers of value to Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs).

In this page, Ipsen EPE discloses nominally any transfers of values to HCPs and the respective values granted/paid to HCOs from 01/01/2017 to 31/12/2017 and the respective consents of the HCPs and HCOs have been received. HCPs and HCOs have the right to access their data and correct any inaccuracies in the disclosed data.

Transfer of Values in relation to Research and Development activities and non-interventional clinical trials are disclosed in an aggregate form.

In any case, this disclosure aims to strengthen transparency to the relations of Pharmaceutical companies and HCPs/HCOs and to support patients' right to be aware of relations of pharmaceutical companies and scientific community.